A new mutation in the CAVIN1/PTRF gene in two siblings with congenital generalized lipodystrophy type 4: case reports and review of the literature
- PMID: 37501786
- PMCID: PMC10369054
- DOI: 10.3389/fendo.2023.1212729
A new mutation in the CAVIN1/PTRF gene in two siblings with congenital generalized lipodystrophy type 4: case reports and review of the literature
Abstract
Lipodystrophy syndromes are characterized by a progressive metabolic impairment secondary to adipose tissue dysfunction and may have a genetic background. Congenital generalized lipodystrophy type 4 (CGL4) is an extremely rare subtype, caused by mutations in the polymerase I and transcript release factor (PTRF) gene. It encodes for a cytoplasmatic protein called caveolae-associated protein 1 (Cavin-1), which, together with caveolin 1, is responsible for the biogenesis of caveolae, being a master regulator of adipose tissue expandability. Cavin-1 is expressed in several tissues, including muscles, thus resulting, when dysfunctional, in a clinical phenotype characterized by the absence of adipose tissue and muscular dystrophy. We herein describe the clinical phenotypes of two siblings in their early childhood, with a phenotype characterized by a generalized reduction of subcutaneous fat, muscular hypertrophy, distinct facial features, myopathy, and atlantoaxial instability. One of the siblings developed paroxysmal supraventricular tachycardia leading to cardiac arrest at 3 months of age. Height and BMI were normal. Blood tests showed elevated CK, a mild increase in liver enzymes and triglycerides levels, and undetectable leptin and adiponectin concentrations. Fasting glucose and HbA1c were normal, while Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) was mildly elevated. Both patients were hyperphagic and had cravings for foods rich in fats and sugars. Genetic testing revealed a novel pathogenic mutation of the CAVIN1/PTRF gene (NM_012232 exon1:c T21A:p.Y7X) at the homozygous state. The diagnosis of lipodystrophy can be challenging, often requiring a multidisciplinary approach, given the pleiotropic effect, involving several tissues. The coexistence of generalized lack of fat, myopathy with elevated CK levels, arrhythmias, gastrointestinal dysmotility, and skeletal abnormalities should prompt the suspicion for the diagnosis of CGL4, although phenotypic variability may occur.
Keywords: CGL4; PTRF; adipose tissue; leptin; lipodystrophy; muscular dystrophy.
Copyright © 2023 Mancioppi, Daffara, Romanisio, Ceccarini, Pelosini, Santini, Bellone, Mellone, Baricich, Rabbone, Aimaretti, Akinci, Giordano and Prodam.
Conflict of interest statement
FP worked as a consultant for the following companies, which are involved with lipodystrophy and/or diabetes: Aegerion/Amryt Pharmaceuticals, Novo Nordisk. BA attended advisory board meetings organized by Amryt Pharmaceuticals and Regeneron Pharmaceuticals and has served as a consultant and/or received honoraria as a speaker from Third Rock Ventures, Amryt, Regeneron, AstraZeneca, Lilly, MSD, Novartis, Novo Nordisk, Boehringer-Ingelheim, Servier, and Sanofi-Aventis. GC has received fees for consulting and/or received travel funds or participated in studies from the following companies, which are involved with lipodystrophy and/or diabetes: Aegerion/Amryt Pharmaceuticals, Novo-Nordisk, and Rhythm Pharmaceuticals. SM received travel funds from the following company, which was involved with lipodystrophy: Amryt Pharmaceuticals. FS has worked as a consultant, participated in studies, and/or received travel funds from the following companies, which are involved with lipodystrophy and/or diabetes: Aegerion/Amryt, Novo Nordisk, Lilly, Bruno Pharma, and Pfizer. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures


Similar articles
-
Congenital generalized lipodystrophy type 4 due to a novel PTRF/CAVIN1 pathogenic variant in a child: effects of metreleptin substitution.J Pediatr Endocrinol Metab. 2022 Apr 11;35(7):946-952. doi: 10.1515/jpem-2022-0022. Print 2022 Jul 26. J Pediatr Endocrinol Metab. 2022. PMID: 35405042
-
Congenital generalized lipodystrophy, type 4 (CGL4) associated with myopathy due to novel PTRF mutations.Am J Med Genet A. 2010 Sep;152A(9):2245-53. doi: 10.1002/ajmg.a.33578. Am J Med Genet A. 2010. PMID: 20684003 Free PMC article.
-
Fatal cardiac arrhythmia and long-QT syndrome in a new form of congenital generalized lipodystrophy with muscle rippling (CGL4) due to PTRF-CAVIN mutations.PLoS Genet. 2010 Mar 12;6(3):e1000874. doi: 10.1371/journal.pgen.1000874. PLoS Genet. 2010. PMID: 20300641 Free PMC article.
-
The spectrum of rippling muscle disease.Muscle Nerve. 2025 Jan;71(1):9-21. doi: 10.1002/mus.28270. Epub 2024 Oct 6. Muscle Nerve. 2025. PMID: 39370631 Review.
-
The worldwide mutational landscape of Berardinelli-Seip congenital lipodystrophy.Mutat Res Rev Mutat Res. 2019 Jul-Sep;781:30-52. doi: 10.1016/j.mrrev.2019.03.005. Epub 2019 Mar 23. Mutat Res Rev Mutat Res. 2019. PMID: 31416577 Review.
Cited by
-
Insulin Delivery Technology for Treatment of Infants with Neonatal Diabetes Mellitus: A Systematic Review.Diabetes Ther. 2024 Nov;15(11):2293-2308. doi: 10.1007/s13300-024-01653-z. Epub 2024 Sep 18. Diabetes Ther. 2024. PMID: 39292435 Free PMC article. Review.
-
Severe Insulin Resistance Syndromes: Clinical Spectrum and Management.Int J Mol Sci. 2025 Jun 13;26(12):5669. doi: 10.3390/ijms26125669. Int J Mol Sci. 2025. PMID: 40565151 Free PMC article. Review.
-
Metabolic and other morbid complications in congenital generalized lipodystrophy type 4.Am J Med Genet A. 2024 Jun;194(6):e63533. doi: 10.1002/ajmg.a.63533. Epub 2024 Jan 17. Am J Med Genet A. 2024. PMID: 38234231 Free PMC article.
-
Siblings With Berardinelli-Seip Congenital Lipodystrophy: Clinical Insights and Challenges.Cureus. 2024 Dec 9;16(12):e75434. doi: 10.7759/cureus.75434. eCollection 2024 Dec. Cureus. 2024. PMID: 39791064 Free PMC article.
-
Analysis of disease characteristics of a large patient cohort with congenital generalized lipodystrophy from the Middle East and North Africa.Orphanet J Rare Dis. 2024 Mar 13;19(1):118. doi: 10.1186/s13023-024-03084-2. Orphanet J Rare Dis. 2024. PMID: 38481246 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials